Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

1 Dupilumab is being jointly developed by Regeneron ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's ...

1 Dupilumab is being jointly developed by Regeneron ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

That's less than the cost of other biologics for severe asthma like GlaxoSmithKline's IL-5 inhibitor Nucala (mepolizumab) and Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...